Systemic treatment and narrowband ultraviolet B differentially affect cardiovascular risk markers in psoriasis - 14/05/14
Abstract |
Background |
Psoriasis is associated with a systemic inflammation and an increased frequency of the metabolic syndrome, both of which are believed to link psoriasis to an increased risk of cardiovascular disease.
Objective |
The study aimed to investigate the systemic expression of markers of cardiovascular risk and determine their response to ultraviolet B therapy and treatment with the tumor necrosis factor-alfa inhibitor, etanercept.
Methods |
Six markers of cardiovascular risk were measured in 28 patients with psoriasis and 28 control subjects.
Results |
Five of the 6 investigated markers were elevated in patients with psoriasis. Four of these correlated to the body mass index and waist-hip ratio, suggesting a link to the metabolic syndrome. Total plasminogen activator inhibitor-1 remained elevated independently of these factors. The levels of the investigated risk markers decreased considerably after tumor necrosis factor-alfa inhibitor treatment but remained unaffected by ultraviolet therapy.
Limitations |
A relatively limited study population and nonrandomization are limitations.
Conclusion |
These findings suggest that the choice of treatment in psoriasis may influence the cardiovascular risk in patients with psoriasis and the metabolic syndrome.
Le texte complet de cet article est disponible en PDF.Key words : cardiovascular risk, matrix metalloproteinase-9, myeloperoxidase, psoriasis, soluble E-selectin, soluble intercellular adhesion molecule-1, soluble vascular cell adhesion molecule-1, total plasminogen activator inhibitor-1, tumor necrosis factor-alfa inhibitor, ultraviolet B
Abbreviations used : Apo-B, BMI, CCL, hs-CRP, ICAM, IL, MMP, MPO, NB, PAI, PASI, sE, sICAM, sVCAM, Th, TNF, tPAI, UV, VCAM, VEGF, WHR
Plan
| Supported by Ingrid Asp Foundation, Welander Foundation, Medical Research Council of Southeast Sweden. |
|
| Disclosure: Dr Ståhle has had speaking and/or advisory board engagements for Pfizer, Abbott, Novartis, and Janssen, and received honoraria for this. She has also served as investigator for Pfizer and Janssen and received grants for this. Drs Sigurdardottir, Ekman, Bivik and Enerbäck have no conflicts of interest to declare. |
|
| Drs Sigurdardottir and Ekman contributed equally to this work. |
Vol 70 - N° 6
P. 1067-1075 - juin 2014 Retour au numéro
Article précédent
- Scoring nail psoriasis
- Karlijn M.G. Klaassen, Peter C.M. van de Kerkhof, Maarten T. Bastiaens, Leon G.J.M. Plusjé, Robert L. Baran, Marcel C. Pasch
- The proactive wet-wrap method with diluted corticosteroids versus emollients in children with atopic dermatitis: A prospective, randomized, double-blind, placebo-controlled trial
- Sherief R. Janmohamed, Arnold P. Oranje, Arjan C. Devillers, Dimitris Rizopoulos, Marinus C.G. van Praag, Dirk Van Gysel, Marleen Goeteyn, Flora B. de Waard-van der Spek
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?